

Press release for immediate release

European Patent Office grants Genomtec with new Patent

Wrocław, Poland - January 20, 2022. - Genomtec S.A. "GMT", a NewConnect listed medical technology company, has received a patent from the European Patent Organization (EPO) for the Genomtec®ID technology and device invented by Genomtec SA. The invention under new patent protection includes Genomtec®ID, the Company's key technology related to a proprietary non-contact heating and temperature sensing system developed for point-of-care testing (POCT) and other applications. This is the first patent granted by EPO and the seventh received by Genomtec. The company has more than twenty patent applications pending worldwide.

"This is a tremendous achievement for us and will protect our invention in our key European market, where we are from and where we received funding to develop our technology and device. Europe is the first and primary market for us to make our genetic diagnostics platform available at the point of care" - said Miron Tokarski, co-founder and CEO of Genomtec SA. "The granting of a patent for our key technology by the European Patent Office, together with the patents already held for it in the United States and Japan, reinforces Genomtec's value to investors and commercial partners." - He adds.

The patent proceedings are aimed at securing key interests and are part of Genomtec's growth strategy, which includes building up its intellectual property rights portfolio within the POCT diagnostics business area.

#####

Additional information at:

Genomtec S.A.

Magdalena Kicińska

+48 604 201 230

m.kicinska@genomtec.com

About Genomtec:

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the GenomtecID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory



setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe. Genomtec was founded in 2016.

GenomtecSA is headquartered in Wrocław.

More information at: www.genomtec.com